Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma

This study tests a new type of cell therapy for multiple myeloma (a cancer of blood plasma cells) that targets two proteins on cancer cells at once — CD19 and BCMA — using specially engineered immune cells called CAR-T cells, for patients whose myeloma has come back or is no longer responding to treatment. **You may be eligible if...** - You have been diagnosed with relapsed or refractory multiple myeloma (cancer that came back or stopped responding) - Your cancer cells test positive for the BCMA protein (confirmed by bone marrow biopsy) - Your disease has not responded to or progressed on standard drugs including bortezomib and lenalidomide - You have no current need for or do not want a stem cell transplant - Your expected survival is more than 12 weeks **You may NOT be eligible if...** - Your overall health is too poor to tolerate intensive therapy - You have certain serious infections (HIV, active hepatitis) - You are pregnant or breastfeeding - Your organ function (heart, liver, kidneys) is significantly impaired - You are currently enrolled in another interventional trial Talk to your doctor to see if this trial is right for you.